Small and mid-cap biotech stocks experienced a significant rebound in 2025, driven primarily by a surge in mergers and acquisitions (M&A). According to Dr. Terry Smith, Director of Life Sciences Research at Emerald Advisers, the sector was like a “coiled spring” after enduring several quarters of underperformance. Multiple factors contributed to this rapid shift in sentiment, including easing headwinds such as lower interest rates, a notable increase in M&A activity, and clearer policies on tariffs and drug pricing.
M&A Activity Fuels Market Recovery
M&A has emerged as a crucial stabilizing force in the biotech industry. Data from JPMorgan indicates that small- and mid-cap companies represented a remarkable 57% of biopharma acquisitions in terms of deal count during the third quarter of 2025. Although the median deal value decreased to $303 million from $516 million in the previous quarter, a total of 33 deals valued at $30.9 billion propelled the M&A volume for 2025 to surpass that of the entire year of 2024.
Johnathon Anderson, CEO of Peptide Systems, noted that the influx of deals has significantly altered risk perceptions within the sector. “This M&A floor has de-risked the sector, allowing investors to chase growth in specific high-tech sub-sectors,” he stated. Dr. Smith echoed this sentiment, emphasizing that consistent mid-sized acquisitions with strong premiums are more beneficial for small-cap investors than a few large-scale transactions.
Shifting Investor Focus in Biotech
While the spotlight in 2024 largely centered on GLP-1 obesity drugs, investor interest in 2025 has shifted towards treatments for cancer and autoimmune diseases, particularly next-generation cell therapies. These include in-vivo and non-viral CAR-T approaches, which promise to be more cost-effective and scalable. Traditional CAR-T therapies, while effective, remain expensive and complex due to the processes involved in cell extraction, lab modification, and reinfusion.
In the last six months alone, approximately $6 billion has been invested in this emerging niche, highlighting significant interest from major pharmaceutical companies.
Several small and mid-cap biotech stocks are attracting investor attention as the sector heads into 2026.
– **BridgeBio Pharma (NASDAQ:BBIO)** focuses on genetic and heart diseases, with its leading heart drug generating over $120 million in revenue in Q3 2025. The company has seen a year-to-date increase of 171.38%.
– **Argenx (NASDAQ:ARGX)**, another success story, has surpassed $1 billion in quarterly product sales. Despite pausing a development program for one eye disease, analysts remain optimistic, with a year-to-date increase of 35.04%.
– **DBV Technologies (NASDAQ:DBVT)** is developing a skin patch to help children build tolerance to peanut allergies. Positive late-stage trial results have positioned the company to seek U.S. approval in early 2026, boasting a year-to-date increase of 500%.
– **Viridian Therapeutics (NASDAQ:VRDN)** targets thyroid eye disease, with promising late-stage trial results and plans for a U.S. launch in 2026. The stock has risen by 63.36% year-to-date.
– **Kyverna Therapeutics (NASDAQ:KYTX)** is exploring one-time immune “reset” treatments for autoimmune diseases like lupus. While still unprofitable, the company has gained 142.09% year-to-date, with a potential upside of 267.11%.
Looking forward to 2026, Elena Meng, a research analyst at Gabelli Funds, anticipates continued M&A activity and strategic partnerships as large pharmaceutical companies seek to replenish their late-stage pipelines, particularly in immunology, rare diseases, and neurology. The current low interest-rate environment is expected to facilitate funding conditions, benefiting firms with credible regulatory paths and imminent catalysts.
Despite this optimism, challenges remain. Dr. Smith pointed out that FDA staff turnover could pose long-term risks, potentially hindering the drug approval process despite current timelines remaining stable. Anderson also noted an “IPO air pocket” resulting from the downturn in the biotech sector during 2023-2024, which has led institutional capital to flow into Private Investment in Public Equity (PIPE) deals, effectively transforming public small-cap biotechs into late-stage venture investments.
